Detalhe da pesquisa
1.
Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
Cell
; 185(12): 2116-2131.e18, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35662412
2.
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.
Cell
; 185(14): 2422-2433.e13, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35772405
3.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell
; 185(3): 467-484.e15, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081335
4.
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
Cell
; 184(9): 2348-2361.e6, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730597
5.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Cell
; 184(8): 2201-2211.e7, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743891
6.
The antigenic anatomy of SARS-CoV-2 receptor binding domain.
Cell
; 184(8): 2183-2200.e22, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33756110
7.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Cell
; 184(23): 5699-5714.e11, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34735795
8.
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Cell
; 184(16): 4220-4236.e13, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34242578
9.
Antibody evasion by the P.1 strain of SARS-CoV-2.
Cell
; 184(11): 2939-2954.e9, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33852911
10.
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Nat Immunol
; 21(3): 354, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001822
11.
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.
Nat Immunol
; 21(11): 1336-1345, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887977
12.
Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.
Nat Immunol
; 19(11): 1248-1256, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30323338
13.
Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
Nat Immunol
; 18(11): 1261-1269, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28945244
14.
Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus.
Nat Immunol
; 17(9): 1102-8, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27339099
15.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet
; 399(10324): 521-529, 2022 02 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074136
16.
Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
Transfus Med
; 31(3): 167-175, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33333627
17.
Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.
Euro Surveill
; 25(42)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33094713
18.
Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
J Infect Dis
; 218(4): 536-545, 2018 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29618091
19.
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
Lancet
; 399(10321): 234-236, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34942101
20.
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.
Nat Commun
; 15(1): 2734, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548763